First post-discharge heart rate and long-term prognosis in patients with acute myocardial infarction

Chuang Li1,†, Qian Zhang1,†, Dejing Feng1,†, Lefeng Wang1, Xinchun Yang1, Pixiong Su1, Kuibao Li1,*, Mulei Chen1,*

1Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chao-Yang Hospital, Capital Medical University, 10020 Beijing, China
*Correspondence: chenmulei5971@126.com (Mulei Chen); kuibaoli@126.com (Kuibao Li)
†These authors contributed equally.

Abstract

Background: Elevated heart rate (HR) is associated with cardiovascular mortality and other events associated with acute myocardial infarction (AMI). The heart rate after discharge is likely superior to reflect the deteriorating heart function, which negatively responds to normal physical activity. This study aimed to explore the effect of HR at the first outpatient visit on clinical outcomes. Methods: We retrospectively identified 605 patients with AMI. HRs at admission, discharge, and first outpatient visits were measured. The primary endpoint was defined as major adverse cardiovascular events (MACEs), including cardiovascular (CV) death, readmission for worsening heart failure, recurrent nonfatal myocardial infarction (MI), repeated coronary revascularization, and ischemic stroke. Results: During the follow-up period, 145 cases of MACE occurred, including 34 CV deaths, 31 recurrent MI, 89 revascularizations, 41 heart failures, and 4 strokes. The event group displayed an elevated HR at the first outpatient visit compared to the event-free group (p < 0.001). After adjustment for confounding risk factors, Cox models showed that the outpatient HR had the best correlation with MACE (Hazard ratio (HR) = 1.33, 95% confidence interval (CI) = 1.052–1.325, p < 0.01) for increments of 1 standard deviation (SD) in the outpatient HR) and CV mortality (HR = 1.18, 95% CI = 1.052–1.325, p < 0.01). The restricted spline model indicated that HR at the first post-discharge above 71 bpm was associated with CV mortality. Conclusions: Elevated HR at the first outpatient visit over a period of 2–4 weeks is related to the adverse outcomes of AMI and may identify AMI patients at higher risk of CV mortality.

Keywords: Acute myocardial infarction; Post-discharge heart rate; Mortality; MACE

1. Introduction

Generally, heart rate (HR) variability and fluctuation after acute and serious disorders directly reflect the severity and complexity of multiorgan dysfunction, especially in the cardiac system. Numerous previous studies have revealed that increased HR is an independent predictor of mortality in a series of cardiovascular (CV) disorders, such as acute myocardial infarction (AMI), stable coronary disease, chronic heart failure, and ischemic stroke [1–5]. Additionally, a series of evidence has been accumulated to identify that different patterns of HR, such as admission HR [6], discharge HR [3,7], HR variability [8] and resting HR [9] have been associated with a higher risk of recurrent myocardial infarction (MI) and long-term mortality in patients with AMI.

Previously, the association between elevated HR on admission and CV mortality during AMI has been recognized and incorporated into different risk stratification models, such as GRACE (Global Registry of Acute Coronary Events) and TIMI (Thrombolysis in Myocardial Infarction) risk scores [7,10]. More recent studies of patients with AMI have reported that the association between discharge HR and long-term mortality is independent and stronger than that with admission HR [1,3]. Although the effects of admission and discharge HR on long-term outcomes after MI have been well established in recent studies, few studies have investigated the effects of post-discharge HR.

Meanwhile, increased HR is believed to be an indicator of more severe conditions for patients with acute coronary syndrome (ACS) [11,12], but there is limited research on the association with outpatient HR during the rehabilitation period. Therefore, this study aimed to explore the relationship between CV events and HR at the first post-discharge visit and the HR difference between discharge and the first outpatient visit (D-O diff).

2. Materials and methods

2.1 Study population

We retrospectively reviewed 6592 AMI patients undergoing primary percutaneous coronary intervention (PCI) at the Beijing Chaoyang Hospital between January 2014 and December 2019, and identified 635 patients with documented first post-discharge vital signs in the outpatient office (Supplementary Fig. 1). The diagnostic criteria for type 2 AMI were in accordance with the fourth universal definition of MI [13] when there is AMI with clinical evidence of myocardial ischemia and detection of a rise in car-
diac troponi (cTn) values with at least above 99th percentile upper reference limit (URL) and at least one of the follow-
ing: (1) typical ischemic symptoms; (2) a newly onset left bundle branch block pattern, or a new ST-segment elevation or depression in at least two contiguous leads, with findings of more than 0.2 mV in leads V1, V2, and V3 or at least 0.1 mV in the remaining leads; (3) the occurrence of pathological Q waves; and (4) new loss of viable myocardium or new regional wall motion abnormally identified by imaging evidence. The exclusion criteria were a life expectancy of less than 6 months due to cancer or cachexia, a history of coronary artery bypass inapplicable to the assessment of SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score, liver cirrhosis, dialysis, and severe infection. Patients with atrial fibrillation and pacemakers were ruled out from this study.

2.2 Clinical measurements and outpatient vital sign

The admission HR and heart rhythm were simultane-
ously measured on an 18 lead electrocardiogram (ECG) and arm electronic sphygmomanometer (OMRON HBP-1300, Omon, Shandong, China) upon arrival to the inpatient department. The discharge HR was measured as the mean value of the last two HR values (resting in the morning before and immediately before discharge). With a routine outpatient review at 2–4 weeks after discharge, the outpatient HR was recorded in the sitting position after resting for 5-
min using an arm electronic sphygmomanometer (OMRON HEM-724 or HEM-1020, Omon, Shandong, China) as the mean value of the two recorded HRs with an interval of 1-min in the department. We calculated the difference be-
tween the two above HRs, such as the D-O difference, by subtracting the first post-discharge visit HR from the value at discharge.

The patients’ baseline information, including clinical features, demographics, and treatment records, were retrospec-
tively collected from the medical database of Bei-
ing Chaoyang Hospital. Laboratory test results, including white blood cell count, hemoglobin, platelet count, low-density lipoprotein, triglyceride, creatinine, fasting glucose, brain natriuretic peptide, and cardiac troponin I (CTNI), were recorded within 12-h after admission. The left ventric-
ular ejection fraction (LVEF) performed by echocardiogra-
phy within 12-h after admission was recorded. The med-
ications were prescribed at discharge and recorded during the first post-discharge review.

In this study, two specialists (CL and DJF) were blinded to the management of medication and the outcomes during follow-up and assessed coronary angiography ac-
cording to the set standards. Coronary single-vessel disease was defined as vessel stenosis >50% in a major coronary artery or in its main branches (diameter >1.5 mm). Multi-
ple vessel disease was defined as stenosis >50% in two or more major coronary arteries. Subsequently, the SYNTAX score was calculated from the initial diagnostic angiogram using an online SS calculator.

This study was approved by the institutional review board of Beijing Chaoyang Hospital and performed in ac-
cordance with the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all the patients or their legal relatives.

2.3 Follow-up review and clinical outcomes

All patients were followed up by routine outpatient visits to assess the development of the disease and the prevalence of major clinical adverse CV events. For pa-
tients without outpatient records, we contacted those pa-
tients by telephone to assess the incidence of CV events. The major adverse cardiovascular event (MACE), which is the primary endpoint of this study, was mainly defined as a composite of CV death, readmission for worsening heart failure, recurrent nonfatal MI, repeated coronary revascularization, and ischemic stroke.

2.4 Statistical analysis

Continuous variables are expressed as mean ± stan-
dard deviation or median with interquartile range, while categorical variables are expressed as frequencies (percent-
ages). Differences between groups were assessed by Stu-
dent’s t-test and one-way analysis of variance (ANOVA) tests for parametric data or Mann–Whitney U or Kruskal–
Wallis nonparametric tests for skewed variables. The corre-
lation of different measures of HR with cardiac function and severity of coronary disease was also investigated. Kaplan–
Meier survival curves were used to evaluate the incidence of MACEs, while the log-rank test was performed to deter-
mine intergroup differences among the groups. Cox propor-
tional hazard regression analysis was performed to identify the predictors of cardiovascular mortality and MACEs. Af-
after adjusting for confounding variables, including sex, age, body mass index (BMI), and other clinical risk parameters, a restricted cubic spline curve was refabricated to present the discharge HR for CV outcomes. To explore the associa-
tion of CV outcomes with different HRs, HR (95% CI) was analyzed for standardized increments of 1 SD of the continu-
ous variables and presented to allow comparisons between the independent predictors. To measure the relative prog-
nostic importance of each HR variable, HRs in hospitals and outpatients were evaluated in individual models, adjusting for the same covariates as in the original predictive model. All statistical tests were two-tailed, and the statistical sig-
nificance was set at \( p \leq 0.05 \). Statistical analyses were per-
formed using STATA (version 15.0, StataCorp, College Sta-
tion, Texas, USA) and R statistical software (version 3.4.0, Ross Ihaka, New Zealand).
3. Results

3.1 Baseline characteristics between groups with and without MACE

Based on the exclusion criteria, 605 AMI patients with first post-discharge vital signs were recruited for this study. The median of follow-up time was 26 months (range: 1–65 months). All subjects were categorized into two groups based on the occurrence of MACE. Table 1 summarizes the baseline characteristics of the two groups. The proportion of patients with and without MACE was 145 (24%) and 460 (76%), respectively. Interestingly, patients in the MACE group presented higher values of admission HR and outpatient HR (75 vs. 80, p = 0.03; 71.4% vs. 76.2%, p < 0.001, respectively), but similar discharge HR (70.7 vs. 70.6%, p = 0.85). Compared with the non-MACE group, patients with MACE were older and had a higher frequency of prior MI, history of PCI, hypertension, and hyperlipidemia, higher levels of admission systolic blood pressure and discharge systolic blood pressure, increased incidence of Killip III or IV levels, and lower LVEF. Based on angiography features, no significant differences in the culprit vessel, number of stenosis arteries, and intra-aortic balloon pump (IABP) were observed, except for a higher SYNTAX score in the MACE group (p = 0.04).

3.2 Kaplan–Meier survival curves and Cox proportional hazards regression

During the average follow-up period of 26 months, 145 (24%) cases with MACE occurred, including 34 CV deaths, 31 recurrent MI, 89 revascularizations, 41 heart failures, and 4 strokes. The patients in the highest quartiles of outpatient HR presented significantly not only a higher cumulative prevalence of MACE and CV mortality, but also an increased incidence of worsening heart failure and ischemic stroke, as indicated by the Kaplan–Meier survival curves (Table 2, Fig. 1). Accordingly, the log-rank test showed significant discrepancies among the four quartiles in terms of CV mortality and MACE.

Based on the Cox proportional hazard regression analysis, the predictors of MACE and CV mortality are shown in Table 3. In the univariate analysis, it revealed that outpatient HR (HR = 1.03, 95% CI = 1.022–1.043, p < 0.001) and admission HR (HR = 1.02, 95% CI = 1.002–1.040, p = 0.04), but not discharge HR (HR = 0.98, 95% CI = 0.942–1.025, p = 0.42) were associated with an increased risk of mortality as well as MACE (HR = 1.02, 95% CI = 1.013–1.031, p < 0.001; HR = 1.01, 95% CI = 1.002–1.022, p = 0.01; HR = 0.99, 95% CI = 0.977–1.016, p = 0.74, respectively). After adjusting for other potential confounders, including age, sex, BMI, admission systolic pressure, administration of β-blockers, levels of hemoglobin and hs-CRP, smoking status, and a history of hypertension, diabetes mellitus, hyperlipidemia, prior MI, and PCI, it indicated that outpatient HR remained an independent powerful predictor of the incidence of CV mortality and MACE (HR = 1.05, 95% CI = 1.020–1.082, p = 0.001 and HR = 1.03, 95% CI = 1.010–1.040, p < 0.01). Accordingly, the restricted cubic spline curve showed that the associations between HR at the first outpatient visit and MACE were approximately linear, while those with CV mortality were nonlinear (Fig. 2).

3.3 Comparison of different measures of HR regarding MACE

As shown in Fig. 3, the standardized HRs for the six types of HRs were calculated for comparison in association with CV mortality and MACE. Each type of HR was used in a multivariate Cox regression model, including age, admission blood pressure, LVEF, prior MI, history of PCI, hypertension, diabetes mellitus, and hyperlipidemia. Notably, HR at the first outpatient visit had the strongest positive association with the occurrence of CV mortality and MACE (HR = 1.33, 95% CI = 10.8%–59.3%, p < 0.01; HR = 1.18, 95% CI = 1.052–1.325, p < 0.01 for increment of 1 SD in outpatient HR). In contrast, 31% risk of CV mortality was reduced by decreased D-O difference HR (HR = 0.69, 95% CI = 0.565–0.846, p < 0.01), while the D-O difference HR was nearly a predictor equal to outpatient HR for MACE (HR = 0.82, 95% CI = 0.726–0.931, p < 0.01 for increment of 1 SD in D-O HR difference). In similarly adjusted models, the association with risk of mortality and MACE for admission HR was attenuated and neutral, with HR of 1.15 (95% CI = 0.837–1.581, p = 0.38) and 1.10 (95% CI = 0.939–1.283, p = 0.24). Meanwhile, no association between discharge HR and A-D difference HR was found for CV mortality and MACE. Interestingly, the A-O difference HR was associated with the risk of CV mortality (HR = 0.79, 95% CI = 0.636–0.979, p = 0.03), whereas no similar result was found for MACE (HR = 0.91, 95% CI = 0.792–1.049, p = 0.20).

4. Discussion

Our findings suggest that the first post-discharge HR is indicative of the risk of MACE in patients with AMI. In addition, this association with CV mortality and morbidity in AMI was independent of and stronger than admission HR and discharge HR, both of which are independently related to mortality, as indicated by previous studies [1,6]. To the best of our knowledge, the present study is the first to illustrate the possibility that the HR at the first post-discharge visit over a recovery period of 2–4 weeks is superior to HR at admission or discharge in predicting long-term CV outcomes in the setting of AMI.

HR is an essential, prognostic, and vital parameter that is very convenient to measure and monitor in clinical practice and may be applicable to therapeutic interventions in coronary artery disease. Several previous studies have established a link between the increased risk of mortality and different patterns of CV events and elevated resting HR [9,14–16]. Kim et al. [4] suggested that worsening the first post-discharge HR control increases the risk of read-
Table 1. Baseline characteristic.

| Factor                      | Non-MACE group | MACE group | p-value |
|-----------------------------|----------------|------------|---------|
| N                           | 460 (76.0%)    | 145 (24.0%)|         |
| age, (year)                 | 61.18 (13.09)  | 65.18 (10.75)| <0.001 |
| Male, n (%)                 | 354 (77.0%)    | 109 (75.2%)| 0.65    |
| BMI, (kg/m²)                | 25.3 (3.76)    | 25.6 (3.37)| 0.42    |
| Diagnosis, n (%)            |                |            | 0.10    |
| STEMI                       | 448 (97.4%)    | 144 (99.3%)|         |
| NSTEMI                      | 12 (2.6%)      | 1 (0.7%)   |         |
| Killip III or IV, n (%)     | 42 (9.1%)      | 18 (12.4%) | <0.001  |
| LVEF, %                     | 62 (53.67)     | 58 (48.64) | <0.001  |
| Outpatient HR, (beat/min)   | 70 (64.75)     | 72 (68.80) | <0.001  |
| Outpatient SBP, (mmHg)      | 125.8 (16.83)  | 127.1 (15.73)| 0.41   |
| Outpatient DBP, (mmHg)      | 74.1 (9.92)    | 73.1 (9.45)| 0.28    |
| Admission SBP, (mmHg)       | 123.1 (20.0)   | 127.8 (21.14)| 0.02  |
| Admission DBP, (mmHg)       | 71.2 (12.86)   | 72.1 (12.01)| 0.52    |
| Discharge SBP, (mmHg)       | 121.0 (13.0)   | 124.5 (14.78)| <0.01 |
| Discharge DBP, (mmHg)       | 70.4 (9.09)    | 71.8 (8.75)| 0.08    |
| Admission HR, (beat/min)    | 75 (66.84)     | 80 (69.86)| 0.03    |
| Discharge HR, (beat/min)    | 70.6 (8.14)    | 70.7 (8.67)| 0.85    |
| Discharge-out diff HR, (beat/min) | –0 (–8, 6)  | –4 (–10, 4)| <0.01  |
| Admi-dis diff HR, (beat/min) | 4 (–4, 15)    | 6 (–3, 15)| 0.17    |
| Admi-out diff HR, (beat/min)| 4 (–4, 14)    | 3 (–5, 14)| 0.43    |
| Medical history             |                |            |         |
| Prior MI, n (%)             | 43 (9.3%)      | 27 (19.0%) | <0.01   |
| History of PCI, n (%)       | 29 (6.3%)      | 22 (15.2%) | <0.001  |
| Diabetes mellitus, n (%)    | 143 (31.1%)    | 56 (38.6%) | 0.09    |
| Hypertension, n (%)         | 240 (52.2%)    | 97 (66.9%) | <0.01   |
| Hyperlipoidemia, n (%)      | 105 (22.8%)    | 45 (31.0%) | 0.05    |
| Smoker, n (%)               | 272 (59.1%)    | 86 (59.3%) | 0.97    |
| Angiography characteristic  |                |            |         |
| Culprit Vessel, n (%)       |                |            | 0.02    |
| LAD, n (%)                  | 178 (38.7%)    | 77 (53.1%) |         |
| LCX, n (%)                  | 71 (15.4%)     | 17 (11.7%) |         |
| RCA, n (%)                  | 209 (45.4%)    | 51 (35.2%) |         |
| LM, n (%)                   | 2 (0.4%)       | 0 (0.0%)   |         |
| Number of stenosis >50% artery |            |            | 0.53    |
| Single vessel, n (%)        | 11 (2.4%)      | 4 (2.8%)   |         |
| Two vessels, n (%)          | 90 (19.6%)     | 20 (13.8%) |         |
| Three vessels, n (%)        | 349 (75.9%)    | 118 (81.4%)|         |
| LM + three vessels, n (%)   | 10 (2.2%)      | 3 (2.1%)   |         |
| IABP, n (%)                 | 188 (40.9%)    | 53 (36.6%) | 0.35    |
| SYNTAX score               | 25.9 (9.98)    | 27.76 (9.33)| 0.04   |
| Laboratoy test              |                |            |         |
| White blood cell, (10⁹/L)   | 10.8 (2.85)    | 11.2 (2.84)| 0.15    |
| Precent of neutral cell, (%)| 79.8 (10.10)   | 79.7 (9.99)| 0.90    |
| Hemoglobin, (10⁹/L)         | 134.9 (17.43)  | 134.2 (15.35)| 0.66  |
| Platelet count, (10⁹/L)     | 216.4 (58.20)  | 215.5 (54.34)| 0.85  |
| Cholesterol, (mmol/L)       | 4.6 (1.06)     | 4.6 (1.12)| 0.95    |
| High density lipoprotein, (mmol/L) | 1.09 (0.29) | 1.13 (0.29)| 0.10  |
Table 1. Continued.

| Factor                        | Non-MACE group | MACE group | p-value |
|-------------------------------|----------------|------------|---------|
| Low density lipoprotein, (mmol/L) | 2.89 (0.88) | 2.84 (0.90) | 0.52    |
| Triglyceride, (mmol/L)        | 1.60 (0.92) | 1.61 (2.70) | 0.91    |
| Fasting glucose, (mmol/L)     | 7.9 (3.74)  | 7.78 (3.30) | 0.74    |
| BNP, (pg/mL)                  | 711.9 (1563.9) | 592.9 (920.6) | 0.39    |
| CTNI, (ng/mL)                 | 63.2 (85.40) | 75.4 (114.4) | 0.17    |
| Hs-CRP, (mg/dL)               | 4.69 (2.10,9) | 4.24 (2.47,11.17) | 0.47    |
| Creatinine, (mmol/L)          | 81.9 (40.30) | 78.90 (21.53) | 0.38    |

Medication at discharge

| Drug     | Non-MACE group | MACE group | p-value |
|----------|----------------|------------|---------|
| Aspirin, n (%)     | 459 (99.8%) | 145 (100.0%) | 0.57    |
| Clopidogrel, n (%) | 445 (96.7%) | 142 (97.9%) | 0.46    |
| Tirofiban, n (%)   | 245 (53.3%) | 85 (58.6%) | 0.26    |
| Ticagrelor, n (%)  | 14 (3.0%)   | 3 (2.1%)   | 0.54    |
| β-blocker, n (%)   | 288 (62.7%) | 92 (63.4%) | 0.88    |
| ACEI/ARB, n (%)    | 238 (51.7%) | 72 (49.7%) | 0.66    |
| Statin, n (%)      | 418 (90.9%) | 127 (87.6%) | 0.25    |
| Nitrogen, n (%)    | 150 (32.6%) | 29 (20.0%) | <0.01   |

Abbreviation: BMI, body mass index; STEMI, ST-segment elevated myocardial infarction; NSTEM, non ST-segment elevated myocardial infarction; LVEF, left ventricular ejection fraction; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; MI, myocardial infarction; PCI, percutaneous coronary intervention; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery; LM, left main artery coronary; IABP, intra-aortic balloon pump; BNP, brain natriuretic peptide; CTNI, cardiac troponin I; Hs-CRP, high-sensitivity C-reactive protein; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker; SYNTAX, Synergy between PCI with Taxus and Cardiac Surgery.

Fig. 1. The Kaplan-Meier curves for (A) CV mortality and (B) MACE among the quartiles of outpatient heart rate. The Kaplan-Meier curve indicated that patients in 4th quartile presented higher prevalence of CV mortality (A) and MACE (B).

Abnormal mission due to the prevalence of CV events in patients with heart failure, including worsening heart failure, non-fatal MI, and mortality. Higher outpatient HR as a continuous parameter was related to an increased risk of mortality, with a hazard ratio of 1.037 (95% CI = 1.029–1.045). In the case of post-MI, the early double-blind Norwegian Timo-lol Multicenter study, Gundersen et al. [17] demonstrated that increased resting HR at 1 month after AMI was related to mortality during a 6-years follow-up regardless of timolol treatment. Although there was no definite descrip-
Table 2. The cumulative incidence of major adverse clinical cardiovascular events by the quartiles of outpatient heart rate.

|                      | 1st quartile | 2nd quartile | 3rd quartile | 4th quartile | p-value |
|----------------------|--------------|--------------|--------------|--------------|---------|
| Number, n (%)        | 153 (25.3%)  | 199 (32.9%)  | 109 (18.0%)  | 144 (23.8%)  |         |
| Follow-up time, (months) | 25 (19, 39)  | 27 (19, 39)  | 25 (11, 38)  | 24 (13, 33)  | 0.02    |
| MACE, n (%)          | 25 (16.3%)   | 42 (21.1%)   | 32 (29.4%)   | 46 (31.9%)   | <0.01   |
| Cardiovascular mortality, n (%) | 4 (2.6%)    | 6 (3.0%)     | 9 (8.3%)     | 15 (10.4%)   | <0.01   |
| Recurrent MI, n (%)  | 13 (8.5%)    | 7 (3.5%)     | 3 (2.8%)     | 9 (6.3%)     | 0.11    |
| Revascularization, n (%) | 15 (9.8%)   | 33 (16.6%)   | 20 (18.3%)   | 21 (14.6%)   | 0.20    |
| Worsening HF, n (%)  | 4 (2.6%)     | 7 (3.5%)     | 12 (11.0%)   | 18 (12.5%)   | <0.001  |
| Ischemia stroke, n (%)| 0 (0.0%)     | 0 (0.0%)     | 0 (0.0%)     | 4 (2.8%)     | <0.01   |

Abbreviation: MACE, major adverse cardiovascular events; MI, myocardial infarction; HF, Heart Failure.

Fig. 2. Restricted cubic spline curve between outpatient HR and CV events and mortality presented as a rough linear relationship. (A) The linear relationship between HR at first post-discharge and CV events. The dashed grey area represents the upper and lower 95% confidence limits. (B) The curve (solid red) shows that a resting HR of 62–71 beats/min was not associated with an elevated risk for CV mortality relative to a resting HR of 61 beats/min.

Interestingly, contrary to the positive results from prior studies regarding the effect of discharge HR on CV mortality, our findings showed that there is a neutral association with clinical outcomes. It is worth noting that the HR at discharge was limited to approximately 70 beats/min in this population. In a recently published study [1], the findings of Alapati et al. [1] also demonstrated that discharge HR <70 bpm has a comparable risk of all-cause mortality compared with HR <60 bpm with a hazard ratio of 0.95. This is consistent with previously published data from two other large-scale studies [2,7] concerning discharge HR. Hence, in the era of timely reperfusion, the effects of β-blockers on long-term prognosis in post-MI patients with HR <70 bpm remains debated [21]. Accordingly, our study found that an outpatient HR >71 bpm was associated with CV mortality in the setting of ACS. Meanwhile, our observation suggested that resting HR in the first visit after discharge rebounded following the recovery of normal physical activity. In the case of post-discharge, activation of the sympathetic nervous system increases further due to normal physical activity, and a hemodynamically unstable phase is expected compared with hospital-
Fig. 3. Comparison of effects between different patterns of heart rate or difference in heart rate on cardiovascular mortality and MACE, respectively. After adjustment for age, admission blood pressure, left ventricular ejection fraction, prior MI, and the history of PCI, hypertension, diabetes mellitus, and hyperlipemia, the outpatient heart rate showed higher risk of CV mortality and MACE, with hazard ratio (HR) of 1.33 and 1.18, respectively. Data from Cox analyses are shown and are expressed as HR (95% CI) for Cox analysis, estimated for increments of 1 SD in each predictive variable.

zation. The condition, referred to as post-hospital syndrome declared by Harlan, suggests that the risks in the critical 30-day period after discharge might be derived from physiological stress and mood anxiety in different scenarios, such as decompensated heart failure and acute coronary disease [22–24]. During hospitalization, a third of patients commonly experience barren sleep, disruption of circadian rhythms, moderate/severe anxiety, and reduction of activity endurance, which can adversely affect sympathetic activity and contribute to diminished physical performance [24]. Among the 7599 patients with chronic heart failure enrolled in the CHARM (candesartan in heart failure: assessment of reduction in mortality and morbidity) research [25], the upward changes in outpatient HR in the three months preceding visit could predict readmission and cardiac death, independent of the series of HR-reducing interventions. A recent study by Ryuichi et al. [26] also indicated that an early follow-up at outpatient management within 2 weeks could improve the long-term rehospitalization rate and composite adverse endpoints, including all-cause mortality in the setting of chronic heart failure. Early follow-up care could consecutively enforce self-management during hospitalization, resulting in an improved prognosis. In the current study, the controlled HR at discharge could contribute to the small number of irresistible events, whereas it remains possible to underestimate the condition of cardiac recov-
|                | Cardiovascular mortality |                | MACE |
|----------------|-------------------------|----------------|------|
|                | Univariate analysis     | Multivariable analysis | Univariate analysis | Multivariable analysis |
|                | HR (95% CI)             | p-value        | HRs (95% CI)      | p-value |
| Age            | 1.04 (1.014–1.076)      | <0.01          | 1.03 (0.987–1.065) | 0.20    | 1.02 (1.007–1.035) | <0.01 | 1.01 (0.996–1.030) | 0.13 |
| Male           | 1.39 (0.666–2.915)      | 0.38           | 1.51 (0.506–2.963) | 0.65    | 1.14 (0.783–1.663) | 0.49  | 1.02 (0.643–1.616) | 0.94 |
| BMI            | 1.10 (1.024–1.188)      | <0.01          | 1.1 (1.033–1.269)  | 0.01    | 1.01 (0.975–1.060) | 0.44  | 1.03 (0.977–1.076) | 0.30 |
| Outpatient HR  | 1.03 (1.022–1.043)      | <0.001         | 1.05 (1.020–1.082) | 0.001   | 1.02 (1.013–1.031) | <0.001| 1.03 (1.010–1.040) | <0.01|
| Admission SBP  | 1.02 (1.007–1.038)      | <0.01          | 1.03 (1.013–1.055) | 0.001   | 1.01 (1.004–1.019) | <0.01 | 1.02 (1.006–1.024) | <0.01|
| Discharge SBP  | 1.01 (0.991–1.036)      | 0.26           |                  |         | 1.01 (1.000–1.021) | 0.04  |                  |      |
| Admission HR   | 1.02 (1.002–1.040)      | 0.03           |                  |         | 1.01 (1.002–1.022) | 0.01  |                  |      |
| Discharge HR   | 0.98 (0.942–1.025)      | 0.42           |                  |         | 0.99 (0.977–1.016) | 0.74  |                  |      |
| Adm-dis HR     | 1.02 (1.004–1.038)      | 0.02           |                  |         | 1.01 (1.001–1.020) | 0.02  |                  |      |
| Adm-out HR     | 0.98 (0.963–0.991)      | 0.001          |                  |         | 0.99 (0.984–1.003) | 0.21  |                  |      |
| Dis-out HR     | 0.96 (0.954–0.976)      | <0.001         |                  |         | 0.98 (0.970–0.988) | <0.001|                  |      |
| Nitrogen       | 0.59 (0.255–1.349)      | 0.01           |                  |         | 0.58 (0.386–0.874) | 0.01  |                  |      |
| β-blocker      | 0.67 (0.332–1.333)      | 0.25           | 0.91 (0.392–2.092) | 0.82    | 1.04 (0.737–1.462) | 0.83  | 0.99 (0.686–1.435) | 0.97 |
| Creatinine     | 1.00 (0.996–1.010)      | 0.36           | 1.00 (0.991–1.011) | 0.81    | 0.99 (0.991–1.002) | 0.33  | 0.99 (0.992–1.004) | 0.57 |
| BNP            | 0.99 (0.999–1.000)      | 0.84           |                  |         | 1.00 (0.999–1.102) | 0.24  |                  |      |
| CTNI           | 1.00 (0.998–1.005)      | 0.38           |                  |         | 1.00 (1.000–1.003) | 0.09  |                  |      |
| EF             | 0.95 (0.917–0.976)      | <0.001         | 0.95 (0.910–0.990) | 0.02    | 0.96 (0.950–0.980) | <0.001| 0.97 (0.950–0.986) | <0.001|
| Hemoglobin     | 1.00 (0.979–1.022)      | 0.98           | 0.99 (0.968–1.015) | 0.47    | 0.99 (0.988–1.008) | 0.66  | 0.99 (0.983–1.005) | 0.33 |
| Hs-CRP         | 1.00 (1.002–1.004)      | <0.001         | 1.00 (1.003–1.006) | <0.001  | 0.99 (0.976–1.021) | 0.91  | 0.98 (0.943–1.018) | 0.30 |
| Current smoker | 1.32 (0.636–2.738)      | 0.46           | 3.81 (1.465–9.299) | <0.01   | 0.99 (0.712–1.386) | 0.97  | 1.31(0.887–1.943) | 0.17 |
| Hypertension   | 2.67 (1.209–5.901)      | 0.02           | 1.10 (0.447–2.720) | 0.83    | 1.68 (1.192–2.381) | 0.02  | 1.15 (0.784–1.695) | 0.47 |
| Diabetes mellitus | 1.78 (0.905–3.505)  | 0.09           | 2.11 (0.994–4.507 ) | 0.05    | 1.50 (1.071–2.094) | 0.04  | 1.28 (0.896–1.843) | 0.17 |
| Hyperlipemia   | 1.76 (0.883–3.531)      | 0.11           | 1.62 (0.690–3.802) | 0.27    | 1.20 (0.850–1.722) | 0.29  | 1.03 (0.692–1.537) | 0.88 |
| Prior MI       | 3.92 (1.912–8.052)      | 0.001          | 2.85 (1.110–7.331) | 0.03    | 1.99 (1.306–3.019) | 0.001 | 1.63 (1.017–2.626) | 0.04 |
| History of PCI | 3.86 (1.741–8.543)      | <0.001         | 3.96 (1.380–11.413) | 0.01    | 2.53 (1.609–3.997) | <0.001| 2.22 (1.342–3.691) | 0.01 |
| SYNTAX score   | 1.02 (0.989–1.049)      | 0.22           |                  |         | 1.013 (0.998–1.027) | 0.08  |                  |      |

Abbreviation: BMI, body mass index; BNP, brain natriuretic peptide; EF, ejection fraction; PCI, percutaneous coronary intervention; HR, heart rate; SBP, systolic blood pressure; CTNI, cardiac troponin I; MI, myocardial infarction.
ery and response to medication. Hence, particular attention needs to be paid to the importance of early follow-up outpatient care, including HR lowering, which could facilitate the management and monitoring of normal daily life habits in the early recovery period.

Our observations suggest that monitoring HR at the first post-discharge visit may be beneficial in identifying AMI patients at the greatest risk of readmission and death. The mechanism beyond the association between outpatient HR and death may relate to a long-term risk of CV autonomic neuropathy in association with various pathogenic pathways, including chronic and atherosclerosis, and infectious disease processes. Reduction of HR variability and baroreflex gain reflect intrinsic autonomic abnormalities, which are generally associated with an imbalance of the autonomic nervous system, including sympathetic hyperactivity and vagal hypoactivity. Therefore, resting tachycardia commonly manifests after AMI, and an exaggerated HR relative to the activation of the sympathetic tone is general [27,28]. Meanwhile, a recent study by Lai et al. [29] indicated that the CV autonomic neuropathy precipitated by diabetes mellitus could contribute to sympathetic predominance and is strongly associated with subsequent major adverse CV events, independent of underlying coronary disease and other risk factors. Several other studies have also shown that autonomic dysfunction, defined as an alteration in vagal and sympathetic activities, is related to long-term CV events [30,31]. Moreover, higher HR is also associated with cardiometabolic factors, such as increased oxidative stress, inflammation markers, glucose intolerance, and diabetes mellitus [28,32]. In the early stage of cardiac resilience following AMI, the discrepancy regarding suboptimal lifestyle habits and CV disease burden and subsequent alterations in myocardial function are also possible contributory factors for uncontrolled resting HR in the clinic department [16,22].

There were several limitations to this retrospective study. First, the research is observational, and as such, cannot establish a cause. Nevertheless, these findings are consistent with those of other studies [4,17]. Second, there was a low rate of CV events in the present study. Standard guideline-directed medical therapy can contribute to a low incidence of CV deaths. Third, the status of chronic inflammatory diseases, such as pulmonary disease, was not depicted in detail in this study. In the Cox proportional hazard regression, when the level of hs-CRP was considered, outpatient HR was an independent risk factor for CV mortality and MACE. Finally, because there was no difference in discharge of β-blockers between the two subgroups, we did not discuss the influence of outpatient β-blocker treatment on the effectiveness of discharge HR for long-term CV events. We did not report the details of patients who received β-blockers in the clinic department. Further research on this relationship should be conducted.

5. Conclusions

In the case of AMI, HR monitoring at the first post-discharge visit is an important parameter associated with CV events. During the first outpatient visit, an HR above 71 beats/min was a risk factor related to the occurrence of CV mortality and other events. Hence, a thorough follow-up of HR changes in outpatients with AMI may facilitate the management of patients at a higher risk of CV events.

Author contributions

CL, DJF and QZ conceived the present study, participated in the design, collected and assembled all data, conducted data analysis, and drafted the manuscript. PXS commented on the manuscript drafts. LFW and XCY provided material and technical support and commented on the manuscript drafts. KBL and MLC aided the interpretation of data, commented on this study design, and provided a critical review. All authors have read and approved the manuscript.

Ethics approval and consent to participate

This study was approved by the institutional review board of Beijing Chaoyang Hospital (2017-S-187) and performed in accordance with the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all the patients or their legal relatives.

Acknowledgment

We would like to express our gratitude to all those who helped us during the writing of this manuscript. We thank all the peer reviewers for their opinions and suggestions.

Funding

This research was funded by the National Key R&D Program of China, grant number 2016YFC1301102. It funded the collection of data in the outpatient department and the revision of the manuscript.

Conflict of interest

The authors declare no conflict of interest.

Supplementary material

Supplementary material associated with this article can be found, in the online version, at https://www.impress.com/journal/RCM/23/1/10.31083/j.rcm2301024.

References

[1] Alapati V, Tang F, Charlap E, Chan PS, Heidenreich PA, Jones PG, et al. Discharge Heart Rate after Hospitalization for Myocardial Infarction and Long-Term Mortality in 2 us Registries. Journal of the American Heart Association. 2019; 8: e010855.
[2] Antoni ML, Boden H, Delgado V, Boersma E, Fox K, Schalij MJ, et al. Relationship between discharge heart rate and mortality in patients after acute myocardial infarction treated with pri-
mary percutaneous coronary intervention. European Heart Journal. 2012; 33: 96–102.

[3] Jensen MT, Kaiser C, Sandsten KE, Alber H, Wanitschek M, Iversen A, et al. Heart rate at discharge and long-term prognosis following percutaneous coronary intervention in stable and acute coronary syndromes — results from the BASKET PROVE trial. International Journal of Cardiology. 2013; 168: 3802–3806.

[4] Kim T, Kim H, Kim J, Yoon H, Park H, Cho Y, et al. Heart rate at first postdischarge visit and outcomes in patients with heart failure. Heart. 2018; 104: 1086–1092.

[5] Kuo Y, Lee M, Huang Y, Lee J. Initial in-hospital heart rate is associated with three-month functional outcomes after acute ischemic stroke. BMC Neurology. 2021; 21: 222.

[6] Noman A, Balasubramaniam K, Das R, Ang D, Kudanian V, Ivanuskiene T, et al. Admission heart rate predicts mortality following primary percutaneous coronary intervention for ST-elevation myocardial infarction: an observational study. Cardiovascular Therapeutics. 2013; 31: 363–369.

[7] Serrone MF, Geha R, Pyunmirat E, Chaib A, Simon T, Berard L, et al. Effect of Vazir A, Claggett B, Jhund P, Teixidó-Tuya G, Kim J, et al. Association of Aortic Stiffness with Left Ventricular Remodeling and Reduced Left Ventricular Function Measured by Magnetic Resonance Imaging: the Multi-ethnic Study of Atherosclerosis. Circulation. Cardiovascular Imaging. 2016; 9: 10.1161/CIRCIMAGING.115.004426.e004426.

[8] Rosello X, Raposeiras-Roubin S, Latini R, Dominguez-Rodriguez A, Barrabes JA, Sanchez PL, et al. Rationale and design of the pragmatic clinical trial IR3eatment with Beta-blockers after myocardial infarction with Out reduced ejection fraction (REBOOT). European Heart Journal - Cardiovascular Pharmacotherapy. 2021. (in press)

[9] Krumholz HM. Post-Hospital Syndrome — an Acquired, Transient Condition of Generalized Risk. New England Journal of Medicine. 2013; 368: 100–102.

[10] Mesquita ET, Cruz LN, Mariano BM, Jorge AJL. Post-Hospital Syndrome: a New Challenge in Cardiovascular Practice. Arquivos Brasileiros De Cardiologia. 2015; 105: 540–544.

[11] Tran H, Byant N, Erskine N, Lessard D, Devereaux RS, Saczynski J, et al. Impact of anxiety on the post-discharge outcomes of patients discharged from the hospital after an acute coronary syndrome. International Journal of Cardiology. 2019; 278: 28–33.

[12] Vazir A, Claggett B, Jhund P, Castagno D, Chugh AR, Teixidó-Tuya G, Kim J, et al. Association of Aortic Stiffness with Left Ventricular Remodeling and Reduced Left Ventricular Function Measured by Magnetic Resonance Imaging: the Multi-ethnic Study of Atherosclerosis. Circulation. Cardiovascular Imaging. 2016; 9: 10.1161/CIRCIMAGING.115.004426.e004426.

[13] Thysen K, Alpert JS, Jaffe AS, Chairman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). Journal of the American College of Cardiology. 2018; 72: 2231–2264.

[14] Auene D, Sen A, o’Hartagh B, Janszky I, Romundstad PR, Torstad S, et al. Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality - a systematic review and dose-response meta-analysis of prospective studies. Nutrition, Metabolism, and Cardiovascular Diseases. 2017; 27: 504–517.

[15] Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. European Heart Journal. 2007; 28: 3012–3019.

[16] Nwabuoc A, Appiah D, Moreira HT, Vasconcellos HD, Aghaj NQ, Ambale-Venkatesh B, et al. Temporal Changes in Resting Heart Rate, Left Ventricular Dysfunction, Heart Failure and Cardiovascular Disease: CARDIA Study. The American Journal of Medicine. 2020; 133: 946–953.

[17] Gundersen T, Grottum P, Pedersen T, Kjekshus JK. Effect of timolol on mortality and reinfarction after acute myocardial infarction: prognostic importance of heart rate at rest. The American Journal of Cardiology. 1986; 58: 20–24.

[18] Motll JE, Whalley GA, Dini PL, Doughty RN, Gamble GD, Klein AL, et al. Independent prognostic importance of a restrictive left ventricular filling pattern after myocardial infarction: an individual patient meta-analysis: Meta-Analysis Research Group in Echocardiography acute myocardial infarction. Circulation. 2008; 117: 2591–2598.

[19] Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nature Reviews. Cardiology. 2011; 8: 369–379.

[20] Ohayma Y, Ambale-Venkatesh B, Noda C, Chugh AR, Teixidó-Tuya G, Kim J, et al. Association of Aortic Stiffness with Left Ventricular Remodeling and Reduced Left Ventricular Function Measured by Magnetic Resonance Imaging: the Multi-ethnic Study of Atherosclerosis. Circulation. Cardiovascular Imaging. 2016; 9: 10.1161/CIRCIMAGING.115.004426.e004426.

[21] Vinik AI, Casellini C, Parson HK, Colberg SR, Nevoret ML. Kuo Y, Lee M, Huang Y, Lee J. Initial in-hospital heart rate is associated with three-month functional outcomes after acute ischemic stroke. BMC Neurology. 2021; 21: 222.

[22] Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Archives of Internal Medicine. 2003; 163: 2345–2353.

[23] Jensen MT, Pereira M, Araujo C, Malmivaara A, Ferrieres J, Degano IR, et al. Heart rate at admission is a predictor of inhospital mortality in patients with acute coronary syndromes: Results from 58 European hospitals: the European Hospital Benchmarking by Outcomes in acute coronary syndrome Processes study. European Heart Journal. Acute Cardiovascular Care. 2018; 7: 149–157.

[24] Zhang D, Wang W, Li F. Association between resting heart rate and coronary artery disease, stroke, sudden death and noncardiovascular diseases: a meta-analysis. Canadian Medical Association Journal. 2017; 188: E384–E392.

[25] Thysen K, Alpert JS, Jaffe AS, Chairman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). Journal of the American College of Cardiology. 2018; 72: 2231–2264.

[26] Aune D, Sen A, o’Hartagh B, Janszky I, Romundstad PR, Torstad S, et al. Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality - a systematic review and dose-response meta-analysis of prospective studies. Nutrition, Metabolism, and Cardiovascular Diseases. 2017; 27: 504–517.

[27] Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. European Heart Journal. 2007; 28: 3012–3019.

[28] Nwabuoc A, Appiah D, Moreira HT, Vasconcellos HD, Aghaj NQ, Ambale-Venkatesh B, et al. Temporal Changes in Resting Heart Rate, Left Ventricular Dysfunction, Heart Failure and Cardiovascular Disease: CARDIA Study. The American Journal of Medicine. 2020; 133: 946–953.

[29] Gundersen T, Grottum P, Pedersen T, Kjekshus JK. Effect of timolol on mortality and reinfarction after acute myocardial infarction: prognostic importance of heart rate at rest. The American Journal of Cardiology. 1986; 58: 20–24.

[30] Motll JE, Whalley GA, Dini PL, Doughty RN, Gamble GD, Klein AL, et al. Independent prognostic importance of a restrictive left ventricular filling pattern after myocardial infarction: an individual patient meta-analysis: Meta-Analysis Research Group in Echocardiography acute myocardial infarction. Circulation. 2008; 117: 2591–2598.

[31] Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nature Reviews. Cardiology. 2011; 8: 369–379.

[32] Ohayma Y, Ambale-Venkatesh B, Noda C, Chugh AR, Teixidó-Tuya G, Kim J, et al. Association of Aortic Stiffness with Left Ventricular Remodeling and Reduced Left Ventricular Function Measured by Magnetic Resonance Imaging: the Multi-ethnic Study of Atherosclerosis. Circulation. Cardiovascular Imaging. 2016; 9: 10.1161/CIRCIMAGING.115.004426.e004426.